Hainan Sparkle Therapeutics Co. Ltd. has described ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Shandong Luye Pharmaceutical Co. Ltd. has divulged cannabidiol prodrugs reported to be useful for the treatment of cancer, tremor, epilepsy, anxiety disorder, inflammatory disorders, pain, multiple sclerosis and Parkinson's disease, among others.
Lifearc has identified pyrimidine compounds acting as serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of chronic myeloid leukemia.
The University of Basel has synthesized triazine derivatives acting as phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders.
Rhizen Pharmaceuticals SA and Incozen Therapeutics Pvt. Ltd. have disclosed salts of NAD+ ADP-ribosyltransferase poly [ADP-ribose] polymerase (PARP) inhibitors reported to be useful for the treatment of cancer, bone, cardiovascular, immunological, inflammatory and respiratory disorders, metabolic diseases and thrombosis.
Cosmas Therapeutics Development Inc. has discovered prodrugs of UCM-924 acting as melatonin MT2 receptor agonists reported to be useful for the treatment of pain, depression, diabetes, sleep and anxiety disorders.
Leitat Technological Center has patented sigma non-opioid intracellular receptor 1 (SIGMAR1) and/or sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain and neurological disorders.
Medipure Holdings Inc. has described cannabidiol (CBD) prodrugs reported to be useful for the treatment of pain, epilepsy, cancer, inflammation, psychosis and neurological, eye and immunological disorders.
Jacobio Pharmaceuticals Co. Ltd. has patented cellular tumor antigen p53 (TP53) (Tyr220Cys mutant) stabilizers reported to be useful for the treatment of cancer.